Jackson Creek Investment Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Jackson Creek Investment Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-32,432	Closed	-$1.01M	–	295
2023 Q4	$1.01M	Buy	32,432 +1	+0%	+$24	0.39%	105
2023 Q3	$676K	Sell	32,431 -14,964	-32%	-$406K	0.29%	189
2023 Q2	$1.14M	Buy	47,395 +2,959	+7%	+$65.8K	0.45%	42
2023 Q1	$836K	Buy	+44,436	New	+$846K	0.35%	145

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Jackson Creek Investment Advisors's ACAD Position: Q1 2024 in Review

Jackson Creek Investment Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q1 2024, closing a stake of 32,432 shares — an estimated $1.01M sold.

Jackson Creek Investment Advisors first reported a position in ACAD in Q1 2023 and held it in 4 quarters. The position peaked at $1.14M in Q2 2023. 267 funds tracked by Wall St. Rank hold ACAD as of Q1 2024.

Jackson Creek Investment Advisors reported no remaining Acadia Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Jackson Creek Investment Advisors sold 32,432 Acadia Pharmaceuticals shares in Q1 2024, an estimated $1.01M.
Jackson Creek Investment Advisors first reported a position in Acadia Pharmaceuticals in Q1 2023 and held it in 4 quarters.
Jackson Creek Investment Advisors's Acadia Pharmaceuticals position peaked at $1.14M in Q2 2023.
267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2024.

Based on Jackson Creek Investment Advisors's 13F filing for Q1 2024, filed 10 May 2024.